Immunogenic Cell Stress and Death
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell Microenvironment".
Deadline for manuscript submissions: closed (15 October 2023) | Viewed by 24164
Special Issue Editors
2. Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France
3. Institut du Cancer Paris CARPEM, Department of Biology, Hôpital Européen Georges Pompidou, AP-HP, 75015 Paris, France
Interests: apoptosis; autophagy; necrosis; tumor immunology
Interests: cancer; immunology; cell death; apoptosis; autophagy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Depending on the initiating stimulus and the premortem stress responses, cell death can be immunogenic or nonimmunogenic. To be immunogenic, malignant or infected cells must be antigenically different from their normal counterparts, and must emit a series of adjuvant signals called danger-associated molecular patterns (DAMPs). It is only the combination of antigenicity and adjuvanticity that confers immunogenicity. Immunogenic cell death (ICD) involves changes in the composition of the cell surface with exposure of DAMPs as well as the release of soluble DAMPs, which must occur in a defined spatiotemporal sequence. Such DAMPs operate on a series of pattern recognition receptors (PRRs) expressed by dendritic cells and their precursors to stimulate the presentation of antigens to cytotoxic T lymphocytes. ICD is cardinal for the activation of the immune system against cancer, which in turn determines the long-term success of anticancer therapies. Moreover, ICD plays a major role in immune responses against infectious pathogens. Of note, both neoplastic cells and viruses have developed strategies to block the exposure or release of ICD-associated DAMPs in order to hide from the immune system. Moreover, acquired or genetically determined defects in the perception of ICD by the immune system subvert immunosurveillance and play a major role in the failure of cancer treatments. The present Special Issue of Cells deals with the identification of therapeutic agents that are particularly efficient in inducing ICD, mostly in the context of cancer.
Dr. Guido Kroemer
Dr. Oliver Kepp
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.